Evolus, Inc. (EOLS)
| Market Cap | 523.78M +28.7% |
| Revenue (ttm) | 316.49M +13.9% |
| Net Income | -34.33M |
| EPS | -0.53 |
| Shares Out | 66.05M |
| PE Ratio | n/a |
| Forward PE | 183.26 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 208,580 |
| Open | 8.33 |
| Previous Close | 8.25 |
| Day's Range | 7.88 - 8.51 |
| 52-Week Range | 3.86 - 9.31 |
| Beta | 1.43 |
| Analysts | Buy |
| Price Target | 15.00 (+89.16%) |
| Est. Earnings | Nov 4, 2026 |
About EOLS
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newpo... [Read more]
Financial Performance
In 2025, Evolus's revenue was $297.18 million, an increase of 11.61% compared to the previous year's $266.27 million. Losses were -$51.64 million, 2.42% more than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for EOLS stock is "Buy." The 12-month stock price target is $15.0, which is an increase of 89.16% from the latest price.
News
Evolus weakness a buying opportunity, says Mizuho
Mizuho notes that Evolus (EOLS) shares were down 8% today and believes the relative underperformance is likely macro-driven and potentially reflective of profit-taking following the stock’s recent out...
Evolus reports Q2 EPS (12c), consensus (4c)
Reports Q2 revenue $84.1M, consensus $81.54M. “The increasing momentum of our portfolio focus has resulted in Evolus (EOLS) gaining significant share across injectable aesthetics during the second qua...
Evolus raises FY26 revenue view to $330M-$337M from $327M-$337M
Consensus $330.45M. Raises adjusted gross profit margin for the full-year 2026 to between 67.0% and 67.5%, from 65.5% to 67.0%, reflecting an evolving revenue mix while maintaining a disciplined appro...
Evolus Earnings Call Transcript: Q2 2026
Q2 2026 saw 21% revenue growth, positive adjusted EBITDA, and expanded international presence. Raised full-year guidance, driven by strong portfolio performance, market share gains, and disciplined financial execution. New product launches and partnerships further support long-term growth.
Evolus Earnings release: Q2 2026
Evolus released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Evolus Slides: Q2 2026
Evolus has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Evolus Quarterly report: Q2 2026
Evolus has published its Q2 2026 quarterly earnings report on August 5, 2026.
Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financi...
Evolus expands strategic partnership with Symatese to commercialize Estyme
Evolus (EOLS) announced it has expanded its partnership with Symatese through an amendment to the companies’ existing licensing and distribution agreement, providing Evolus with the exclusive rights t...
Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has expa...
Evolus Slides: Scientific Investor presentation
Evolus has posted slides in relation to its latest quarterly earnings report, which was published on August 3, 2026.
Evolus to Report Second Quarter Financial Results on August 5, 2026
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will repor...
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant during Ap...
Evolus partners with IBSA to develop and market Profhilo in the U.S.
Evolus (EOLS) has entered into an exclusive licensing and distribution agreement with IBSA, a Swiss multinational pharmaceutical company, to develop and commercialize Profhilo in the U.S. Profhilo is ...
Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has ente...
Evolus Transcript: AGM 2026
The meeting confirmed quorum, presented three proposals, and all were approved by shareholders. No questions were raised during the Q&A, and the meeting was conducted virtually with proper notice.
Evolus files $250M mixed securities shelf
16:47 EDT Evolus (EOLS) files $250M mixed securities shelf
Evolus Registration statement: Registration filing
Evolus filed a registration statement on June 5, 2026, providing details about a securities offering with the SEC.
Evolus management to meet virtually with BTIG
Medical Technology Analyst Eiber holds a Virtual Meeting with Management on June 11 hosted by BTIG.
Evolus Transcript: Jefferies Global Healthcare Conference 2026
The company has evolved into a diversified aesthetics platform, expanding internationally and leveraging digital efficiencies for scalable growth. Product innovation, especially in HA injectables, and strong clinic partnerships drive market share gains. GLP-1 trends and a robust pipeline support long-term growth and profitability.
Evolus to Participate in The Jefferies Global Healthcare Conference
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced members of its man...
Evolus announces commercial launch of Estyme in Europe
Evolus (EOLS) announced that the commercial launch of Estyme, its injectable hyaluronic acid gel collection in Europe, is scheduled for May 16th, marking the company’s entry into the international der...
Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that the co...
Evolus Earnings Call Transcript: Q1 2026
Q1 results showed 7% revenue growth, positive Adjusted EBITDA, and strong Jeuveau performance. Guidance for 2026 and long-term outlook remain unchanged, with double-digit revenue growth and margin expansion expected. Tariff risks are being proactively managed.
Evolus Earnings release: Q1 2026
Evolus released its Q1 2026 earnings on May 4, 2026, summarizing the period's financial results.